🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesGLP-1 and gluconeogenesis — May 2025 Page 2

GLP-1 and gluconeogenesis — May 2025

sarah_nash92 Wed, Mar 26, 2025 at 6:16 PM 9 replies 1,616 viewsPage 2 of 2
VendorMark
Senior Member
3,456
14,567
Jan 2024
Texas
Online
Mar 27, 2025 at 8:24 PM#6
pete_manc_UK said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

My labs after 3 months on glycaemic control: A1C 6.4%, fasting glucose 79 mg/dL, fasting insulin 6 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.3% and fasting glucose was 124 mg/dL. The improvement has been dramatic and consistent.

11 6DebRD_ATL, KristenIndy, MarkLI_maint and 8 others
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Mar 28, 2025 at 6:50 AM#7
sarah_nash92 said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)117998983
Insulin (fasting)231396
HOMA-IR5.53.81.71.1
Uric Acid8.56.75.64.8

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.

10 5AmyNC_wife, SkepticalSean, Dr.CardioMD and 7 others
Reply Quote Save Share Report
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Mar 28, 2025 at 5:16 PM#8
VendorMark said:
My labs after 3 months on glycaemic control: A1C 6.4%, fasting glucose 79 mg/dL, fasting insulin 6 uIU/mL.

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 4.9 (insulin resistant) → Current = 1.5 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

9 4laura_annarbor, JenMemphis, pat_auckland and 6 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
lori_vegas
Member
378
1,678
Aug 2024
Las Vegas, NV
Mar 29, 2025 at 3:42 AM#9

One thing that is still open after tommy_boulder’s answer:

Was that from a primary source or from a summary of one?

Last edited: Mar 29, 2025 at 5:42 AM
8 3tane_welly, Dr.PathRoch, mona_PHX and 5 others
Reply Quote Save Share Report
sarah_nash92
Member
712
3,123
Jun 2024
Nashville, TN
Mar 31, 2025 at 5:48 AM#10
Dr.NutriCornell said:
Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking: HOMA-IR = (fasting…

Fasting insulin is the lab my functional medicine doctor cares about most for glycaemic control: it's a much earlier marker of metabolic dysfunction than glucose or A1C.

My fasting insulin: 23 → 15 → 5 uIU/mL over 9 months. Target is <7. By the time your fasting glucose is elevated, your insulin has been elevated for YEARS trying to compensate.

Ask your doctor to include fasting insulin in your bloodwork panel. It's cheap (~$20) and incredibly informative.

26 24KetoKyle, CanadaChris, ZaraB_AL and 23 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register